First data for immunitybio's memory cytokine-enriched nk cells in small cell lung cancer at sitc meeting show promising anti-tumor activity

Culver city, calif.--(business wire)--immunitybio, inc. (nasdaq: ibrx), a clinical-stage immunotherapy company, today announced new data showing that the company's memory cytokine-enriched natural killer cells (m-cenk) may provide benefit to patients with small cell lung cancer and patients with other types of neuroendocrine tumors. findings from the study titled “characterization of the anti-tumor activity of memory cytokine enriched nk cells (m-cenk) against tumors with neuroendocrine feature.
IBRX Ratings Summary
IBRX Quant Ranking